RNA (1999), 5:395–408. Cambridge University Press. Printed in the USA. Copyright © 1999 RNA Society.

Structural alterations of the tRNA(m¹G37)methyltransferase from *Salmonella typhimurium* affect tRNA substrate specificity

JI-NONG LI and GLENN R. BJÖRK

Department of Microbiology, Umeå University, S-901 87 Umeå, Sweden

ABSTRACT

In Salmonella typhimurium, the tRNA(m¹G37)methyltransferase (the product of the trmD gene) catalyzes the formation of m¹G37, which is present adjacent and 3' of the anticodon (position 37) in seven tRNA species, two of which are tRNA^{Pro}_{CGG} and tRNA^{Pro}_{CGG}. These two tRNA species also exist as +1 frameshift suppressor sufA6 and sufB2, respectively, both having an extra G in the anticodon loop next to and 3' of m¹G37. The wild-type form of the tRNA(m¹G37)methyltransferase efficiently methylates these mutant tRNAs. We have characterized one class of mutant forms of the tRNA(m¹G37)methyltransferase that does not methylate the sufA6 tRNA and thereby induce extensive frameshifting resulting in a nonviable cell. Accordingly, pseudorevertants of strains containing such a mutated trmD allele in conjunction with the sufA6 allele had reduced frameshifting activity caused by either a 9-nt duplication in the sufA6 tRNA or a deletion of its structural gene, or by an increased level of m¹G37 in the sufA6 tRNA. However, the sufB2 tRNA as well as the wild-type counterparts of these two tRNAs are efficiently methylated by this class of structural altered tRNA(m¹G37)methyltransferase. Two other mutations (trmD3, trmD10) were found to reduce the methylation of all potential tRNA substrates and therefore primarily affect the catalytic activity of the enzyme. We conclude that all mutations except two (trmD3 and trmD10) do not primarily affect the catalytic activity, but rather the substrate specificity of the tRNA, because, unlike the wild-type form of the enzyme, they recognize and methylate the wild-type but not an altered form of a tRNA. Moreover, we show that the TrmD peptide is present in catalytic excess in the cell.

Keywords: 1-methylguanosine; modification; recognition

INTRODUCTION

Transfer RNAs from all organisms contain modified nucleosides (Björk, 1995; Sprinzl et al., 1998) that are derivatives of the four normal nucleosides, adenosine (A), guanosine (G), uridine (U) and cytosine (C). The nucleoside modifications occur after transcription, once the polynucleotide has been formed (Svensson et al., 1963). A few modified nucleosides, for example pseudouridine and 5-methyluridine, are present in all tRNA species in a given organism, whereas most of the modified nucleosides are present in a subset of tRNAs. The enzymes catalyzing the formation of this latter type of modified nucleoside must therefore recognize this subset of tRNAs and disregard all other tRNAs as substrates. As many as 15 modified nucleosides are present in corresponding positions in tRNAs from the three domains—Archaea, Bacteria, and Eucarya (Björk, 1986; Cermakian & Cedergren, 1998). This suggests a common evolutionary origin for these modified nucleosides (Björk, 1986; Cermakian & Cedergren, 1998) and indicates that the tRNA present in the progenitor may have contained these modified nucleosides. One of these conserved modified nucleosides is 1-methylguanosine (m¹G), present in position 37 (adjacent to and 3' of the anticodon) in tRNAs from all organisms' reading codons of the type C(U,C)N and CGG, that is, tRNA-specific for leucine, proline, and arginine (Björk, 1995). The formation of m¹G37 is catalyzed by the tRNA(m¹G37)methyltransferase, which uses AdoMet as methyl donor. Evidently, this enzyme must both bind the AdoMet and exclusively recognize this subset of tRNAs. The enzymes in the various organisms of today may, therefore, besides having the conserved AdoMet binding motif, also contain conserved features reflecting common recognition determinants. Indeed, the tRNA(m¹G37)methyltransferase has stretches of amino acids with high similarity between organisms as evo-

Reprint requests to: Glenn R. Björk, Department of Microbiology, Umeå University, S-90187 Umeå, Sweden; e-mail: Glenn.Bjork @micro.umu.se.

lutionary far apart as *Salmonella typhimurium* (official designation, *Salmonella enterica* serovar Typhimurium) and *Mycoplasma* (Fig. 1). The function of this enzyme and the way it recognizes the tRNA may therefore be similar among various bacterial species and perhaps even in other organisms.

There have been several reports that address the question of which sequences in the tRNA are deter-

mining the specificity and the efficiency of the tRNA modification reaction (see, e.g., Droogmans et al., 1986; Edqvist et al., 1994; Nakanishi et al., 1994; Björk, 1995; Curnow & Garcia, 1995; Grosjean et al., 1996; Gu et al., 1996, 1998; Motorin et al., 1997; Qian & Björk, 1997; Redlak et al., 1997). However, only one report has addressed the question of which features of a tRNA-modifying enzyme are involved in tRNA binding

Name: st <i>trmD</i>	Salmonella typhimurium trmD
Name: ec <i>trmD</i>	Escherichia coli trmD
Name: sm <i>trmD</i>	Serratia marcescens trmD
Name: hitrmD	Haemophilus influenzae trmD
Name: bstrmD	Bacillus subtilis trmD
Name: ac <i>trmD</i>	Acinetobacter calcoaceticus trmD
Name: sstrmD	Synechocystis sp. trmD
Name: hp <i>trmd</i>	Helicobacter pylori trmD
Name: bbtrmD	Borrelia burgdorferi trmD
Name: ml <i>trmD</i>	Mycobacterium leprae trmD
Name: mt <i>trmD</i>	Mycobacterium tuberculosis trmD
Name: mp <i>trmD</i>	Mycoplasma pneumoniae trmD
Name: mg <i>trmD</i>	Mycoplasma genitalium trmD



		D22(I)	
	61	D2(F)	120
sttrmd	LMMVQPLRDAIHAAKAAAGEGAK <mark>VI</mark> YLSI		
ectrmd	LMMVQ <mark>PLRDATHAAKAAAGEGAKVT</mark> YLSH		
smtrmd	LMMVQPLREATHAAKAAAGEGAK <mark>VT</mark> YLSI		
hitrmd	I.MMVQPI.RDAIHTAKAAAGEGAK <mark>VT</mark> YI.SI		
bstrmd	V KPQPVFDAVEDLTSKAAAAPRII	Q <mark>C</mark> ERFTOKKAEQLAKEEHLLFICG	HYEGYDE
actrmd	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		~~~~~~
sstrmd	VIKPEPIFAAVESLPVLSKREVTLMT		
hptrmd	ILDPEMVENALHSVKNPKHTIFLSA		
bbtrmd	VLKAEPISFALEHVESAKKTTIFLSI		
mltrmd	VMKAPVWGEALDEICFDETLLVIPT	ACALFTQATAQCWSTERHLVFACC	RYEGIDQ
mttrmd	VMKAPVWGEALDEICSSETLLIVPT		
mptrmd			
mgtrmd	VIKAEPTINCLNFYKAPNSHVVLLSI	ECEQFSONCAKKITKYEHI. TISC	HYEGEDQ

FIGURE 1. (Legend on facing page.)

396

		<i>D11</i> (T)	
	121	D10(S)	172
sttrmd	RVIQTEIDEEWSI	GDYVLS G GELP A MELIDSV	ARFIPGVLGH.E <mark>AS</mark> AIED.SFA
			SR <mark>FIPGVLG</mark> H.E <mark>AS</mark> ATED.SFA
smtrmd			ARFTPGVLGH.QASAEED.SFA
			ARETPGVLGK.QASAEED.SFA
			VRLLPGVLGK.EASHIED.SFS
			IRRIPDAMSD.EQSHIQD.SFV
			IRLE <mark>PGTVC</mark> K.E <mark>AS</mark> LIAE.SFS
			AR <mark>HIQ</mark> GVLGNAQSLEN <mark>E</mark> SFENHYL
			YRLID <mark>GVINP.NSL</mark> LE <mark>FS</mark> FGVK
			LRLVA <mark>GVLG</mark> N.PASHRDDSHSPDL
			LRLLA <mark>GVLG</mark> N.P <mark>AS</mark> HQD <mark>D</mark> SHSTGL
mptrmd	RIYK.HVDQI SI	GDEVLSGGEL <mark>VALSV</mark> ID <mark>AT</mark>	VRLIKGV_ND.QSLIHESFN
mgtrmd	RIYK.YIDQIVSL	CDEVLSGCEL <mark>VALSV</mark> ID <mark>AT</mark>	WRLTKGV ND.QSLICESFN

	D3(L)	233
sttrmd	DGLLDCPHYTREEVIEGMEVPPVLLSGNHAEIRRWRLKQSLGRTWLRRPEI	LENLALTEE
ectrmd		20022
smtrmd		
hitrmd		
bstrmd		
actrmd	DGLLD <mark>C</mark> PQYTKPDHFECDVPEVLKSCHHANLEKWRFLQRYQRTLDRRPEL	VEKVTLTKQ
sstrmd	TDLLDYPHYTRPPVFRCMAVPPVLLSGNHQAIAQWRLEQQEERTQQRRPDL	WQKWQDRQP
hptrmd		
bbtrmd	NGLL YPHYTRPYDFKG KVPEVLLSGHHANIKNWRLVKAREKTKKNRYDL	YLKYLEIIG
mltrmd	GRLLEGPSYTRPPTWRGIDVPPVLLSGDHARIAAWRREASLRRTRKRRPDL	SGARFVWGL
mttrmd	DCLLEGPSYTRPASWRGIDVPEVLLSCDHARIAAWRREVSLQRTRERRPDL	SHPD*~~~~
mptrmd	NYLLDFPAYTRPYDIDGDKVPEILLSCDHKKIEAYRKEQQLLRTAQYRPDL	YKQYLAKKD
mgtrmd	UNILLDFFVVYTRPYDI.KGDKVFEVILSCDHQKIESFRKEQQIIKTAKYRPDI	YKKYLENKN

D22(*)

		DEE()	
	234	<i>D1</i> (K)	256
sttrmd	QARLLA	EFKT E HA Q Q	QHKHDGMA*
ectrmd	QARLLA	EFKTEHAQQ	QHKHDGMA*
smtrmd	QAVLLA	EFQREHQAR	QQDYEG~~~
hitrmd	QRKLLK	EAQAEHNS*·	~~~~~~~
bstrmd	QRKWIS	EWEKE*~~~	~~~~~~~~~
actrmd	QRKWLT	FLDDSKN~~~	~~~~~~~
sstrmd	SP*~~~	~~~~~~	~~~~~~~~
hptrmd	~~~~~	~~~~~~~	~~~~~~~
bbtrmd	EDNGFD	KKN*~~~~~	~~~~~~~~
mltrmd	GLS*~~	~~~~~	~~~~~~~~
mttrmd	~~~~~	~~~~~	~~~~~~~~
mptrmd	EKNK*~	~~~~~~	~~~~~~
mgtrmd	EKNK*T	~~~~~~~	~~~~~~~

FIGURE 1. Deduced amino acid sequence of the *trmD* gene from *S. typhimurium* and alignment of all the known TrmD sequences obtained from the database using the box and shade program. Numbers above the alignment correlate to amino acid positions in *S. typhimurium* and amino acid substitutions identified in different mutants are underlined. Black shade indicates identical amino acids and gray shade indicate similar amino acids. The stop codons are marked with asterisks. The putative S-adenosyl methionine binding site is also underlined. The *Acinetobacter calcoaceticus trmD* gene is only partially sequenced. Translational starts of the *trmD* genes from the two *Mycoplasma* species are not identified.

398

(Romier et al., 1996). Although the three-dimensional structure of enzyme-tRNA complex is required to fully understand in detail how a tRNA-modifying enzyme recognizes the tRNA substrate, identification of those amino acids that are influencing tRNA substrate specificity is a first step in such an analysis. Such information will be valuable when the three-dimensional structure is known to identify which surface of the enzyme is engaged in the tRNA recognition. As a first step to identify such amino acids in a tRNA-modifying enzyme, we have characterized mutant forms of the tRNA(m¹G37)methyltransferase that do not methylate a structurally altered tRNA, but are still able to methylate its wild-type counterpart.

RESULTS

Isolation and genetic characterization of *trmD* mutants

sufA6 is a derivative of the major proline tRNA^{Pro}_{CGG} (Riddle & Roth, 1970) and functions as a +1 frameshift suppressor at CCC-U site (CCC is in the zero frame, a +1 frameshift moves the ribosome to the CC-U codon). The wild-type (Kuchino et al., 1984) as well as the sufA6 tRNA (see below) contain m¹G adjacent to and 3' of the anticodon. The absence of m¹G37 reduces the rate with which the tRNAPro isoacceptors are selected at the ribosomal A-site (Li et al., 1997). Therefore, lack of this modified nucleoside may reduce the activity of the frameshifting suppressor tRNA if it is poorly selected. Since m¹G37 also prevents frameshifting (Björk et al., 1989), the lack of it in the sufA6 derivative of tRNA^{Pro}_{CGG} may also increase the frameshifting activity. Thus, by monitoring the frameshifting activity we may isolate mutations in the trmD gene that either reduce or increase the frameshifting activity of the sufA6 tRNA^{Pro}_{CGG} caused by the lack of m^1G37 . We also screened for mutants unable to grow at high temperature on rich medium. Such potential trmD mutations were combined with another frameshift suppressor mutation, sufB2, which is a G insertion in the anticodon loop of another proline tRNA species, the tRNA^{Pro}_{GGG}. The *sufB2* tRNA is also a substrate for the wild-type tRNA(m¹G37)methyltransferase. By comparing the phenotype of these double mutants (trmD, sufA6 versus trmD, sufB2) and the single mutant (trmD), we tried to identify structural alterations in the TrmD peptide that mediated different ability to methylate these two mutant forms of tRNA^{Pro}_{CGG} and tRNA^{Pro}_{GGG} as well as their wild-type counterparts.

A stock of phage P22 grown on strain TT126 (*tyrA555::*Tn10) was treated with hydroxylamine (Hong & Ames, 1971) to mutagenize the *trmD* gene that is 52% linked to *tyrA* (Björk et al., 1989). Strain TR1457 (*sufA6, hisO1242, hisD3749*) was used as recipient.

The hisD3749 mutation is a C insertion resulting in the sequence CCC-UGA, which can be suppressed by the +1 frameshift suppressor sufA6 (CCC is in the zero frame, a +1 frameshift moves the ribosome to the CC-U codon). Among the Tet^R transductants selected, we screened for His⁻ clones and also tested the growth ability at high temperature on rich medium. All transductants were His⁺, indicating that no mutations were obtained that reduced the activity of the sufA6 tRNA^{Pro}_{CGG} as a +1 frameshift suppressor. However, several mutants were obtained that were unable to grow at high temperature on rich medium. Introduction of various plasmids harboring the *trmD*⁺ gene from *Escherichia* coli or the vector control showed that all these mutations were in the *trmD* gene (data not shown; for the trmD3 mutation and experimental design, see Björk et al., 1989). Based on various phenotypes, these mutations were divided into three classes (Table 1). Only the trmD3 mutation caused a temperature-sensitivegrowth phenotype in the absence of any other mutations (Class III). Furthermore, only this mutation mediated the ability to suppress +1 frameshift mutations at 37 °C (Björk et al., 1989). Mutations trmD1, D2, D17 and D22 were not temperature sensitive alone or in combination with the sufB2 allele (Class I), whereas two mutations, *trmD10* and to some degree *trmD11*, induced temperature sensitivity when combined with the sufB2 allele (Class II).

TABLE 1.	Phenotypes	induced	by	the	three	classes	
of <i>trmD</i> m	utations.						

Class	trmD	suf	Growth on rich plate at 42.5 °Cª	Suppression of <i>hisD3749</i> at 37 °C ^b
	0	+	++	_
		A6	++	++
		B2	++	++
1	D1; D2; D17; D22	+	++	_
		A6	_	++
		B2	++	++
П	D10; D11	+	++	_
		A6	_	++
		B2	+	++
111	D3	+	+	+
		A6	_	++
		B2	-	++

^aGrowth of indicated strains were monitored on agar plates following incubation at 42.5 °C for 24 h before the size of the colonies were scored. ++: colonies as large as the colonies formed by the wild-type cell; +: small colonies; and -: no colonies formed. All strains (GT5473, GT5475, GT5477, GT5479, GT2772, GT2774, GT2780, GT2784) contained the *tyrA555::Tn10*, *hisO1242*, and the *hisD3749* mutations and the indicated *trmD* allele.

^bFrameshift suppressor activity was scored as the ability to suppress the frameshift mutations *hisD3749* or *hisD3018*. ++: growth was observed after 12 h incubation at 37 °C on minimal plate lacking His. +: growth was observed after 24 h incubation under the same condition; -: no growth was observed after 3 days.

J.-N. Li and G.R. Björk

Sequence alterations in the *trmD* gene induced by the various mutations

The *trmD* gene from 13 bacterial species, *E. coli*, *S. typhimurium*, *Serratia marcescens*, *Hemophilus influenzae*, *Bacillus subtilis*, *Synechocystis sp.*, *Borrelia burgdorferi*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Helocobacter pylori*, and *Acinetobacter calcoaceticus* (partly), have been sequenced and are aligned in Figure 1.

Chromosomal fragments carrying the *trmD* gene from the different trmD mutants were amplified by PCR and sequenced. Amino acid changes mediated by the mutations are presented in Figure 1. Three class I mutations (trmD2, 17 and 22) mediate changes within the first 100 amino acids in the N-terminus of the 255amino-acid-long TrmD peptide: L94F (trmD2); A25T (trmD1); and V99I, Q246Stop(trmD22). However, the trmD1 mutation, which phenotypically belonged to the class I mutations, was found to result in a change close to the C-terminus of the enzyme (E243K). This was close to one of the two mutations in the Class I mutant trmD22. The trmD3 mutation (the only Class III obtained) caused an amino acid alteration in position 184 (P184L). The two class II mutations (trmD10 and D11) whose phenotypes are in between the class I and class III mutations had the amino acid substitutions, G140S and A145T, respectively. These mutations were not far from the class III mutation trmD3 in position 184. Interestingly, most of the mutations obtained induced changes in conserved positions (Fig. 1) but none changed the highly conserved putative AdoMet binding site (three out of seven positions are identical in all species). Any mutation in the AdoMet binding site would most likely affect the methylation reaction but not necessarily the tRNA substrate specificity. This suggests that the mutations characterized affected some important features in the interaction between the TrmD protein and the tRNA, the expression, or the stability of the enzyme.

Effects of the *trmD* mutations on the level and the activity of the TrmD protein

Introduction of various mutations in the *trmD* gene may influence the synthesis, stability, or the catalytic activity of the TrmD protein. Changes in these parameters may result in m¹G-deficient tRNAs. Therefore, we measured the level of m¹G in total tRNA by high performance liquid chromatography (HPLC), and in specific tRNA species by thin-layer chromatography. Moreover, we monitored by Western blot analysis the steadystate level of the TrmD protein. As shown in Figure 2 and Table 2 all but one (*trmD10*) mutation reduced the level of the TrmD peptide to various degrees. The reduction was more pronounced at 42 °C compared to


37 °C. Among the mutations tested, trmD1 and trmD22 reduced the steady-state level of the respective protein by more than 50% at 42 °C. Both these mutations caused changes in the C-terminal part of the TrmD peptide (trmD1, E243K and trmD22, Q246stop; trmD22 has an additional mutation, Q246Stop). The trmD1 mutant has at 42 °C only 16% of the wild-type level of the peptide, but is still able to fully modify the wild-type tRNAs (Table 2). The TrmD3 and the TrmD10 peptides, however, have reduced modification capacity but relatively much higher level of the respective peptide as compared to TrmD1. This suggests that the trmD3 and the trmD10 mutations must affect primarily the catalytic activity of the enzyme, whereas the trmD1 mutation does not. This is also true for all other mutations in Class I as well as the trmD11 mutation of Class II (Table 1). These results suggest also that TrmD peptide is normally present in catalytic excess in the cell.

Growth ability of the *trmD*, *suf* mutants at high temperature reflects the level of m¹G37 in tRNA

In the presence of the *sufA6* allele, all *trmD* mutants were temperature sensitive for growth. However, they behaved differently in the presence of the *sufB2* allele (classification based on this phenotype, Table 1). To investigate whether the presence of different mutant tRNAs affects the modification level and therefore the cell growth, we prepared bulk and specific tRNAs from the double mutant strains. *trmD1* was chosen as a representative of the Class I mutants and *trmD3* of Class III.

Both the sufA6 tRNA^{Pro}_{CGG} (this work) and the sufB2 tRNA^{Pro}_{GGG} (Sroga et al., 1992) has a G insertion in the anticodon loop. These two tRNA species were fully methylated by the wild-type (TrmD⁺) enzyme and the strains carrying the *sufA6* or the *sufB2* mutation grew normally at 42.5 °C (Table 3). We also know that m¹G is adjacent to and 3' of the anticodon in these mutant tRNAs, as it is in their wild-type counterparts (Qian et al., 1998). Therefore a G insertion in the anticodon loop of these tRNA species does not affect the substrate specificity of the wild-type form of the enzyme. Also the TrmD1 peptide methylated efficiently the wildtype and the *sufB2* tRNAs at 42 °C (Table 2). Since the trmD1, sufA6 strain did not grow at high temperature, a shift of temperature was performed after the culture had been pregrown at 30 °C. In such a shift experiment, a tenfold increase in mass occurred before the cells stopped growing, because the tRNA made at 30 °C is fully methylated and therefore allows the cell to grow, albeit at reduced rate. By this method we were able to prepare tRNA from the trmD1, sufA6 strain at 42 °C and found that no m¹G was synthesized (Table 3). Since the TrmD3 peptide is functionally inactive, even in the presence of the wild-type substrate tRNAs at 37 °C

D* D1 D2 D3 D10 D11 D17 D22 pBY03/K12



	Integrated intensity	trmD ⁺	trmD1	trmD2	trmD3	trmD10	trmD11	trmD17	trmD22
	TrmD/ProX	0.64±0.03	0.20±0.07	0.62±0.11	0.49±0.07	0.78±0.08	0.43±0.05	0.69±0.10	0.34±0.05
37°C	Mu/Wt	1	0.32±0.12	0.97±0.13	0.75±0.12	1.2±0.1	0.64±0.08	1.1±0.1	0.53±0.10
	TrmD/ProX	0.91±0.09	0.15±0.07	0.66±0.17	0.50±0.10	0.91±0.05	0.56±0.13	0.68±0.08	0.30±0.10
42°C	Mu/Wt	1	0.16±0.06	0.72±0.12	0.55±0.05	0.97±0.05	0.59±0.08	0.75±0.02	0.32±0.08

FIGURE 2. Level in vivo of the TrmD polypeptide in different *trmD* mutants (GT5473, GT5475, GT5477, GT5479, GT2772, GT2774, GT2780, GT2784). The various strains are only differing in the allelic state of the *trmD* gene. Cells were grown at 37 °C or 42 °C (gel not shown) and cell extracts containing 20 μ g of protein prepared from each strain were electrophoresed on a SDS-15% polyacrylamide gel. TrmD protein was visualized by immunoblotting with polyclonal antiserum directed against TrmD and the streptavidin-HRP labeled secondary antibody specific for rabbit Ig. An unknown protein (ProX), which was present at the same level in all extracts, was used as an internal control and the intensity of each band was quantified with a Howtek scanmaster 3+. A wild-type *E. coli* strain carrying a plasmid overexpressing the *trmD* gene (pBY03/*K12*) was used as a marker to identify the TrmD polypeptide. One of the two mutations in the *trmD22* mutant introduced a stop codon at amino acid 246 and therefore gave rise to a 10-amino-acid-shorter product. The values presented in the table are the average of two or three independent measurements with experimental errors indicated.

(Table 2), no m¹G should be expected in the *trmD3*, *sufA6* or the *trmD3*, *sufB2* double mutants at high temperature (these two strains do not grow at all at 42 °C, as at 30 °C they already are deficient in m¹G37). Thus, all these strains that cannot grow at high temperature, the *trmD1*, *sufA6* and the *trmD3*, *sufA6* or *trmD3*, *sufB2*, were also deficient of m¹G. By Western blot analysis, we found that the level of the TrmD1 protein was reduced upon introduction of the *sufA6* allele, but not upon introduction of the *sufB2* allele (Table 3). Therefore, the lack of m¹G in the *trmD1*, *sufA6* mutant is correlated to the reduced level of the TrmD1 polypeptide in this particular strain. In contrast, the level of the TrmD3 polypeptide was reduced upon introduction of either the *sufA6* or the *sufA6* allele (Table 3).

Extensive frameshifting by the *sufA6* tRNA causes reduction of the TrmD1 and the TrmD3 peptides

To further analyze how the different mutant TrmD peptides and the substrate tRNAs in combination induced a temperature-sensitive phenotype, we isolated spontaneous temperature resistant revertants of the double mutants *trmD1*, *sufA6* and *trmD3*, *sufA6*. These revertants were isolated at a frequency of 10^{-6} – 10^{-7} and genetic and biochemical characterizations are summarized in Table 3.

Two classes of revertants derived from the trmD1, sufA6 double mutant were characterized (at least two independent isolates from each class were analyzed and were caused by the same mutational event). Both classes had lost their frameshift suppressor activity and the mutations were linked to the sufA6 allele. The sufA6 mutation, similar to the sufB2 mutation established by Sroga et al. (1992), was shown to have an extra G inserted in the anticodon loop (Fig. 3). One class of the revertants, trmD1, sufA6+9, had a duplication of a 9-ntlong DNA sequence corresponding to A39 to G47 in the *sufA6* tRNA^{Pro}_{CGG} sequence. The resulting tRNA^{Pro}_{CGG} can be drawn in the cloverleaf form as having an extended variable loop (14 nt instead of 5; Fig. 3) besides retaining the extra G in the anticodon loop. The second class of the revertants, the *trmD1*, $\Delta sufA6$ revertant,

TABLE 2. Growth ability	and m ¹ G	level in tRNAs	of various	trmD or	suf mutants.
-------------------------	----------------------	----------------	------------	---------	--------------

	Growth	Suppression	10	Level of TrmD 37 °C ^d				
Relevant genetic markers	at 42.5 °Cª	of <i>hisD3749</i> at 37 °C ^b	m ¹ G level in bulk tRNA 37 °C°	tRNA ^{Pro} CGG	tRNA ^{Pro} CGG tRNA ^{Pro} GCGG		Mutation identified	
wt	++	_	0.13 ± 0.02 0.15 ± 0.02 (42 °C)	0.93	1.1	1		
sufA6	++	++	$\begin{array}{l} 0.12\pm0.00\\ 0.14\pm0.01\ (42^\circ C) \end{array}$	1.2 ± 0.3	ND ^g	0.89 ± 0.09	$+G$ in the anticodon of $tRNA_{CGC}^{\text{Pro}}$	
sufB2	++	++	0.12 ± 0.01 0.14 (42 °C)	ND	1.0 ± 0.2	1.0 ± 0.1	$+G$ in the anticodon of $tRNA_{GGC}^{Pro}$	
trmD1 (Class I ^g)	++	_	0.14 0.13 (42 °C)	1.3 ± 0.1	1.0 ± 0.1	0.32 ± 0.12	E243K substitution in <i>trmD</i>	
<i>trmD2</i> (Class I ^g)	++	-	0.14 0.14 (42 °C)	ND ^f	ND ^f	0.97	L94F substitution in trmD	
trmD10 (Class II)	++	_	$\begin{array}{c} 0.075\pm0\\ 0.087 \end{array}$	ND ^f	ND ^f	1.2	G140S substitution in trmD	
trmD11 (Class II)	++	_	$\begin{array}{c} 0.12 \pm 0.03 \\ 0.13 \end{array}$	ND ^f	ND ^f	0.64	A145T substitution in <i>trmD</i>	
trmD3 (Class III)	+	+	0.018 ± 0.003 <0.01 (42 °C)	undetectable	undetectable	0.75 ± 0.12	P184L substitution in <i>trmD</i>	

^aGrowth of strains were monitored on agar plates following incubation at 42.5 °C for 24 h before the sizes of the colonies were scored. ++: colonies as large as those of the wild-type cells; +: medium; and -: no colonies formed. All strains (GT5473, GT476, GT477, GT5475, GT5479, GT686, GT2732, GT3162, GT2756, GT3645, GT3647, GT3649, GT3651) used contain the *hisO1242* and *hisD3749* or *hisD3018* or *hisC3737* alleles and the indicated alleles of the *trmD* gene, the *sufA6* or the *sufB2* alleles.

^b++: growth was observed after 12 h incubation at 37 °C on glucose minimal plate lacking His; +: growth after 24 h; (+): weak growth after 48 h incubation; -: no growth was observed after 3 days under the same condition.

^{c,d}The level of m¹G in bulk tRNAs are presented as the amount of m¹G relative to the amount of Ψ . Level of m¹G in *sufA6* tRNA or its derivatives are presented as mole of m¹G per mole of tRNA. Experimental variations are shown when more than one (2–3) measurements were performed.

^eLevels of TrmD polypeptide of cells grown at 37 °C were measured as described in Figure 2.

^fND: not determined.

^gThe two other Class I mutants, *trmD17* and *trmD22*, had 0.12 \pm 0.01 and 0.13 \pm 0.01 m¹G per Ψ in tRNA from cells grown at 37 °C.

had an 18-nt-long deletion within the structural gene (proK) for tRNA^{Pro}_{CGG}. This corresponded to nt A59 to A76 in the tRNA. A Northern blot experiment using a DNA probe specific for the anticodon region of tRNA^{Pro}_{CGG} confirmed that this tRNA species was not present in the cell (data not shown). Thus, although tRNA^{Pro}_{CGG} is a major tRNA species, it is not essential for growth. The tRNA^{Pro}_{CGG} from the *trmD1*, *sufA6*+9 revertant was overexpressed (more than fivefold) and partially (8.5%) aminoacylated as measured by Northern blot using an acidic gel (data not shown, for experimental design see Materials and Methods). Since the revertant trmD1, sufA6+9 was also unable to suppress the hisD3749 mutation, the extended variable loop may counteract the frameshifting ability induced by the G insertion in the anticodon. Alternatively, because tRNA^{Pro}_{CGG} is nonessential, this mutant form of the tRNA^{Pro}_{CGG} with its 9-nt duplication might be unable to function in the decoding step of translation although it is able to partially accept amino acid in vivo. The sufA6+9 mutation mediated an 8.5-fold increase and the deletion of *sufA6* mediated a fourfold increase in the level of the TrmD1 polypeptide as compared to that

in the *trmD1*, *sufA6* strain (Table 3). Thus, a correlation exists between low frameshifting activity and a high level of the TrmD peptide. Moreover, these findings suggest that the cause of lethality induced by the *trmD1* mutation in the *trmD1*, *sufA6* mutant is a too extensive frameshifting by the unmethylated *sufA6* tRNA.

Two classes of revertants were characterized from the trmD3, sufA6 double mutant (also in this case at least two independent isolates of each class were analyzed and were caused by the same mutational events). The first Class *trmD3*, *sufA6-A* revertants appeared as large colonies as the wild-type cells at 42.5 °C and the frameshift suppressor activity of the revertants was reduced but not completely abolished as scored by the His-phenotype (Table 3). This revertant had a deletion of an A in the anticodon loop of the sufA6 tRNA (Fig. 3). This created a tRNA that has the same sequence as the wild-type tRNA^{Pro}_{CGG} except for a base substitution in the anticodon loop (A38 to G38). The level of m¹G in this tRNA species was increased from 0 to 0.37 mole per mole tRNA. In bulk tRNA, an increase from 0.014 to 0.042 mole m¹G per Ψ was observed, which can be attributed to the increased

402

J.-N. Li and G.R. Björk

		Growth	Suppression	101 111	Level of m ¹	G (37 °C)e		
trmD allele	suf allele	at 42.5 °Cª	of <i>hisD3749</i> at 37 °C ^b	m ¹ G level in bulk tRNA 37C ^d	tRNA ^{Pro} CGG	tRNA ^{Pro} GGG	Level of TrmD 37 °C ^f	Mutation identified
trmD1	sufB2	++	++	0.12 ± 0.03 0.13 ± 0.01 (42 °C)	1.2	0.97 ± 0.14	0.36 ± 0.03	
	sufA6	-	++c	$0.14 \pm 0.02 < 0.01(42 ^{\circ}\text{C})$	0.80 ± 0.2	0.73 ± 0.02	0.03 ± 0.01	
	<i>sufA6</i> +9 (Rev.)	++	-	0.11 ± 0.02	0.24 ± 0.05	ND ^g	0.25 ± 0.06	+9 nt in <i>sufA6</i> tRNA
	$\Delta sufA6$ (Rev.)	++	_	0.082 ± 0.014^{h}	ND ^g	ND ^g	0.12 ± 0.04	Deletion of sufA6 tRNA
trmD3	sufB2	_	++	ND ⁱ	ND ^g	ND ^g	0.03 ± 0.02	
	sufA6	-	++	0.014	undetectable	ND ^g	0.08 ± 0	
	<i>sufA6-A</i> (Rev.)	++	(+)	0.042 ± 0.003	0.37	ND ^g	0.43 ± 0.05	GGGG instead of GGGGA in the anticodon of <i>sufA6</i> tRNA
<i>trmD3</i> , <i>trmD23</i> (Rev)	sufA6	+	+	0.08 ± 0.02	0.44	ND ^g	1.8 ± 0.2	$\label{eq:tgggg} \begin{array}{l} TGGGGGA \to TGGGGGG \\ in \ \textit{trmD} \ SD\text{-sequence} \end{array}$

^aGrowth of strains was monitored on agar plates following incubation at 42.5 °C for 24 h before the sizes of the colonies were scored. ++: colonies as large as those of the wild-type cells; +: medium; and -: no colonies formed. All strains (GT5473, GT476, GT477, GT5475, GT5479, GT686, GT2732, GT3162, GT2756, GT3645, GT3647, GT3649, GT3651) used contain the *hisO1242* and *hisD3749* or *hisD3018* or *hisC3737* alleles and the indicated alleles of the *trmD* gene, the *sufA6*, or the *sufB2* alleles.

^b++: growth was observed after 12 h incubation at 37 °C on glucose minimal plate lacking His; +: growth after 24 h; (+): weak growth after 48 h incubation; -: no growth was observed after 3 days under the same condition.

^cMucoid.

^{d,e}The level of m¹G in bulk tRNAs is presented as the amount of m¹G relative to the amount of Ψ . Level of m¹G in *sufA6* tRNA or its derivatives is presented as mole of m¹G per mole of tRNA. Experimental variations are shown when more than one (2–3) measurements were performed.

^fLevels of TrmD polypeptide of cells grown at 37 °C were measured as described in Figure 2.

^gND: not determined.

^htRNA^{Pro}_{CGG} contributes to 29% of the total m¹G content (calculated according to Riddle & Roth, 1972; Ikemura, 1981). The observed reduction in m¹G in *trmD1*, Δ*sufA6* double mutant can be attributed entirely to the absence of tRNA^{Pro}_{CGG} and therefore the other tRNA species contain the normal level of m¹G37.

ⁱThe strain containing both *trmD3* and *sufB2* mutations was not possible to grow in liquid medium because the mutations lysed and quickly reverted before reaching a cell density suitable for preparing tRNA.

level of m¹G in *sufA6-A* tRNA, as it is a major tRNA (Table 3). Thus, the *sufA6-A* tRNA with its normal-sized anticodon loop is a better substrate for the TrmD3 polypeptide as compared to the *sufA6* tRNA with its oversized anticodon loop.

The other class of revertants, trmD3, sufA6, trmD23, was still able to frameshift, although less efficiently compared to its parent, the double mutant trmD3, sufA6. The trmD23 mutation was found to be linked to the trmD gene and sequence analysis showed that the mutation was an A-to-G change at -8 in the putative translation initiation region (TIR)(TGGGGG instead of TGG GGA). Compared to the original double mutant trmD3, sufA6, which has no m¹G37 in tRNA^{Pro}_{CGG} and only about 10% of the wild-type level of m¹G37 in bulk tRNA, 44% of the *sufA6* tRNA had regained m¹G and 80% of the bulk tRNA was modified in the revertant strain (Table 3). The changed Shine-Dalgarno sequence increased the synthesis of the TrmD3 polypeptide, resulting in an increased synthesis of m¹G37. A Western blot experiment using antibody against the TrmD polypeptide showed that the amount of the TrmD3 polypeptide was indeed increased 23-fold compared to that in the *trmD3*, *sufA6* mutant (Table 3). Similarly, but to a lesser extent (fivefold), the TrmD polypeptide was also increased in the *trmD3*, *sufA6-A* revertant. This is consistent with a correlation between a low frameshifting activity and an increased level of the TrmD polypeptide.

In summary, the analysis of the revertants obtained from class I (*trmD1*, *sufA6*) and from class III (*trmD3*, *sufA6*) mutants showed that in both cases the revertants had reduced frameshifting activities. This was correlated with an increased ability to methylate the tRNA and an increased synthesis of the mutated TrmD peptide. The cause of lethality in the double mutants seems to be an extensive frameshifting activity mediated by the unmethylated *sufA6* tRNA.

DISCUSSION

In this work, we have described the isolation and characterization of various mutant forms of the tRNA(m^1G37)methyltransferase of *S. typhimurium* encoded by the *trmD* gene. The enzyme is highly con-




FIGURE 3. Cloverleaf structure of tRNA $_{GG}^{PN}$ (Kuchino et al., 1984) and of *sufB2* tRNA (Qian et al., 1998). Only the anticodon region and the variable loop are shown for the mutant derivatives of the *sufA6* tRNA. A in the *sufA6* and in the *sufB2* tRNAs indicates the position of the inserted G adjacent and 3' of the m¹G37 (Qian et al., 1998). The revertant *sufA6-A* has deleted an A (symbolically drawn outside the tRNA) compared to the *sufA6* tRNA resulting in tRNA with a normal sized anticodon loop and an A38 to G38 base substitution compared to the wild-type *proK* tRNA. The *sufA6+9* tRNA has an internal nine base duplication (bold triangles) creating in the cloverleaf model an extended variable loop.

served among closely related organisms such as *E. coli, S. marcescens*, and *H. influenzae* (92%, 84%, and 78% identities, respectively, to *S. typhimurium*) but also conserved in many regions among more distantly related species such as *Mycoplasma* (Fig. 1). These conserved regions must be functionally important, as the same subset of tRNAs are modified at the same position in all these organisms and most *trmD* mutations obtained in this work were changed in these highly conserved positions.

The *sufA6* tRNA, which has an extra G 3' of m¹G37 as compared to its wild-type form tRNA^{Pro}_{CGG} (Fig. 3), induces +1 frameshifting at CCC-N sites (Riddle & Roth, 1970) (CCC is in the zero frame and a +1 frameshift moves the ribosome to the CC-N codon). Also lack of

m¹G37, induced by the *trmD3* mutation, mediates +1 frameshifting at similar sites (Björk et al., 1989). Combining the *sufA6* mutation with the *trmD3* mutation therefore results in a hypomethylated derivative of the *sufA6* tRNA at 42 °C and such a double mutant is not viable at this temperature (Table 3). The fact that whereas a small amount of m¹G is present at 37 °C in the *trmD3* mutant, no m¹G was detected at 42 °C (Table 2) raises the question of why the observed lethality at 42 °C of these double mutants is correlated to lack of m¹G at this temperature. We suggest that the reason for lethality of these double mutants is extensive frameshifting; that is, the undermethylated derivative of these frameshifting tRNA are inducing more +1 frameshifting than the methylated derivative of them. Indeed, using a

plasmid in which the lacZ gene expression is dependent on a +1 frameshifting event at a CCC-U site, a higher β -galactosidase activity was observed in these double mutants as compared to the sufA6 or sufB2 single mutants (Q. Qian & G.R. Björk, unpubl.). The TrmD3 peptide is also strongly reduced in these double mutants, suggesting that its synthesis is affected by extensive frameshifting. Indeed, a potential frameshifting site (CCC-U) is present in the structural gene of trmD at codon 66. A frameshifting event at this site will result in premature termination after translation has proceeded for an additional 17 amino acids in the +1 frame. The truncated polypeptide is most likely not functional and will be quickly degraded. Thus, the results obtained with the double mutants trmD3, sufA6 and trmD3, sufB2 suggest that lack of m¹G37 in these tRNAs causes extensive frameshifting that also affects the level of the TrmD3 peptide, perhaps by a +1 frameshifting event early in the trmD mRNA.

In contrast to the *trmD3* mutation, the Class I mutation *trmD1* has normal capacity to methylate wild-type tRNA and causes temperature sensitivity only in the presence of the *sufA6* allele (Table 4). A reduced capacity to methylate tRNA and a reduction of the level of the TrmD1 peptide was observed in the *trmD1*, *sufA6* double mutant (Table 3). This phenotype is reminiscent of that shown by the double mutant *trmD3*, *sufA6*, which suggests that the TrmD1 peptide, like the TrmD3 peptide, does not methylate the *sufA6* tRNA. Lack of m¹G37 in the sufA6 tRNA results in an extensive +1 frameshifting and consequently a reduced level of the TrmD1 peptide. Indeed, using the same plasmid as above in which the *lacZ* gene expression is dependent on the +1 frameshifting event at a CCC-U site, a tenfold higher β -galactosidase activity was observed in the *trmD1*, sufA6 mutant compared to that in the sufA6 mutant (Q. Qian, J.-N. Li, & G.R. Björk, unpubl. result). These results suggest that the TrmD1 polypeptide recognizes inefficiently the sufA6 tRNA with its extra G in the anticodon loop, although it fully methylates its wild-type $(proK^+)$ counterpart and the *sufB2* tRNA as well as its wild-type ($proL^+$) counterpart. Note that the wild-type form of the enzyme does not discriminate between these two forms of the same tRNA, as it fully methylates these tRNAs (Table 2). Thus, we suggest that the E243K alteration in the TrmD1 polypeptide influences primarily the substrate specificity, which results in a discrimination between the $proK^+$ and sufA6 tRNA substrates only differing in the insertion of a G in the anticodon loop of the sufA6 tRNA.

Earlier we suggested that the reason for the temperature sensitivity of the *trmD1*, *sufA6* double mutant is extensive frameshifting caused by the inability of the TrmD1 peptide to methylate *sufA6* tRNA. A further

TABLE 4. S. typhimurium strains used in this study.

Name	Genetic characteristics	Source
LT2	wt	John Roth
GT476(TR1457)	hisO1242, hisD3749, sufA6	John Roth
GT477(TR936)	hisO1242, hisD3018, sufB2	John Roth
GT686	hisO1242, hisC3737, tyrA555::Tn10, trmD1, sufA6	This work
GT688	hisO1242, hisC3737, tyrA555::Tn10, trmD2, sufA6	This work
GT907	metA22, metE551, ilv-452, trpB2, xyl-404, rpsL120, flaA66, hsdL66, hsdA29, galE503	
GT2677	hisO1242, hisD3749, tyrA555::Tn10, trmD10, sufA6	This work
GT2678	hisO1242, hisD3749, tyrA555::Tn10, trmD11, sufA6	This work
GT2685	hisO1242, hisD3749, tyrA555::Tn10, trmD17, sufA6	This work
GT2690	hisO1242, hisD3749, tyrA555::Tn10, trmD22, sufA6	This work
GT2732	hisO1242, hisD3749, tyrA555::Tn10, trmD3, sufA6	This work
GT2750	hisO1242, hisD3018, tyrA555::Tn10, trmD10, sufB2	This work
GT2752	hisO1242, hisD3018, tyrA555::Tn10, trmD11, sufB2	This work
GT2756	hisO1242, hisD3018, tyrA555::Tn10, trmD3, sufB2	This work
GT2772	hisO1242, hisD3749, tyrA555::Tn10, trmD10	This work
GT2774	hisO1242, hisD3749, tyrA555::Tn10, trmD11	This work
GT2780	hisO1242, hisD3749, tyrA555::Tn10, trmD17	This work
GT2784	hisO1242, hisD3749, tyrA555::Tn10, trmD22	This work
GT3162	hisO1242, hisD3018, tyrA555::Tn10, trmD1, sufB2	This work
GT3164	hisO1242, hisD3018, tyrA555::Tn10, trmD2, sufB2	This work
GT3645	hisO1242, hisC3737, tyrA555::Tn10, trmD1, sufA6+9	This work
GT3647	hisO1242, hisC3737, tyrA555::Tn10, trmD1, ∆sufA6	This work
GT3649	hisO1242, hisD3749, tyrA555::Tn10, trmD3, sufA6-A	This work
GT3651	hisO1242, hisD3749, tyrA555::Tn10, trmD3, trmD23	This work
GT5473	hisO1242, hisD3749, tyrA555::Tn10, trmD+	This work
GT5475	hisO1242, hisD3749, tyrA555::Tn10, trmD1	This work
GT5477	hisO1242, hisD3749, tyrA555::Tn10, trmD2	This work
GT5479	hisO1242, hisD3749, tyrA555::Tn10, trmD3	This work

404

support for this interpretation is our analysis of the temperature-resistant revertants isolated from the trmD1, sufA6 and the trmD3, sufA6 double mutants. Although these pseudorevertants are distinct, the underlying mechanism by which they were isolated may be the same-they all in different ways reduce or abolish the frameshifting activity of the m¹G37 deficient sufA6 tRNA. The TrmD3 peptide has a reduced catalytic activity (Table 2) and therefore the revertants isolated from the trmD3, sufA6 double mutant resulted in an increased modification capacity either by changing the tRNA to a better substrate (*sufA6-A*) for the TrmD3 peptide or by increasing the synthesis of the TrmD3 peptide (the trmD23 mutation alters the sequence of the putative Shin-Dalgarno sequence of the trmD mRNA; Table 3). On the other hand, the TrmD1 peptide fails to recognize the *sufA6* tRNA but modifies normally other tRNAs; that is, its catalytic activity is normal if tRNAs other than sufA6 tRNA are the substrates (Tables 2 and 3). Therefore, the isolated revertants had either lost the sufA6 gene (Δ sufA6) or the tRNA was changed to a nonframeshifting derivative (sufA6+9). When the *sufA6+9* mutation (isolated as a revertant of trmD1, sufA6) was introduced into the various trmD, sufA6 double mutants, the growth deficiency was only partially suppressed in the trmD3, sufA6 mutant, but fully suppressed in the double mutants containing any of the Class I mutations (data not shown). This suggests that all Class I mutations induce the same type of physiological defect(s) as the *trmD1* mutation and, as stated above, they may all influence the tRNA substrate specificity.

These results are consistent with our suggestion, as discussed above, that the *trmD1* mutation and also the other Class I mutations influence primarily the tRNA substrate specificity, whereas the *trmD3* mutation has more influence on the catalytic activity in general. The allele specificity demonstrates that the TrmD1 polypeptide must interact in a distinct way with the *sufA6* tRNA compared to the TrmD3 peptide, and that this TrmD1-*sufA6* tRNA interaction can be counteracted by changes in the *sufA6* tRNA that is not counteracting the interaction(s) between the TrmD3 and *sufA6* tRNA. Clearly, the aberrant interaction between TrmD1-*sufA6* tRNA and the TrmD3-*sufA6* tRNA is different as the respective pseudorevertants isolated showed allele specificity.

Both *sufA6* and *sufB2* mutations induce strong frameshifting as monitored by their ability to suppress the *hisD3749* mutation, which contains the CCC-U potential frameshifting site. Still, these two frameshift suppressors did not significantly influence the level of the TrmD peptide (Table 3), although the same putative frameshifting site (CCC-U) is present in the *trmD* mRNA. However, even a very low *his*-expression (less than 1% of the wild-type *his*-expression; Riddle & Roth, 1970) results in His⁺ phenotype. Indeed, the *his*-system is much more sensitive at monitoring frameshifting than many other systems are, for example, using a plasmid in which the *lacZ* gene expression is dependent on a +1 frameshifting event at the same frameshifting site (Qian et al., 1998). Thus, although the sufA6 and sufB2 frameshift suppressor tRNAs are reasonably strong as monitored by the His-phenotype, they may not induce frequent frameshift events at the many putative CCC-N sites that are present in the genome. Indeed, the growth rates in rich medium of these two mutants are similar to that of the wild-type strain (Table 2; see also Riddle & Roth, 1970), suggesting that significant frameshifting at many CCC-N sites may not occur and one such site seems to be the one present in the *trmD* gene. Strong frameshifting at this site apparently requires that the m¹G37 is absent, which creates an anticodon of 4 (sufA6) or 5(sufB2) Gs in a row (Fig. 3) as compared to only 2 (sufA6) or 3 (sufB2) Gs in a row in trmD+ background (Fig. 3; presence of m¹G37 prevents Watson–Crick pairing with C; Newmark & Cantor, 1968). According to the new model of +1 frameshifting (Qian et al., 1998), the creation of a row of G in the anticodon may facilitate +1 slippage in the P-site and thereby induce a frameshifting event. Therefore, lack of m¹G37 in these frameshift suppressor tRNAs makes them able to induce a frameshifting event at most of the CCC-N sites present in the genome, resulting in a nonviable cell.

All Class I mutations [trmD1 (E243K), trmD2 (L94F), trmD17 (A25T), and trmD22 (V99I, Q246stop)] mediate alterations either in the N- or C-terminal part of the peptide. These mutations do not affect the modification of the wild-type tRNA even though the levels of the TrmD proteins were reduced. One mutant of this class, the trmD1, had the lowest amount of the TrmD polypeptide among all mutants isolated (32% of the wildtype level at 37 °C and 16% of the wild-type level at 42 °C); still the tRNAs were fully methylated even at 42 °C (Fig. 2, Table 2). This reduction of the TrmD1 level is not correlated to any observed increase in frameshifting as monitored by the suppression of the hisD3749 mutation. Therefore, the TrmD1 peptide seems to be intrinsically more unstable than the wild-type TrmD⁺ peptide. Moreover, in the double mutant trmD1, sufA6 grown at 37 °C, surprisingly, only 3% of the wild-type level of the TrmD1 polypeptide was observed and still the level of m¹G37 in tRNA was the same or nearly the same as in the wild type (Table 3). Thus, the level of the TrmD polypeptide seems to be in surplus in relation to the need to methylate tRNA. Also the MiaA polypeptide, which catalyzes the first step in the formation of ms²i⁶A in tRNA reading codons starting with U, is present in catalytic excess (Leung et al., 1997). Whether this will be true for other tRNA modifying enzymes awaits further analysis. Still the tRNA modifying enzymes are present in low amount in the cell compared to other proteins involved in translation.

406

MATERIALS AND METHODS

Abbreviations

The enzyme (E.C. 2.1.1.31) that catalyzes the formation of 1-methylguanosine (m¹G) adjacent and 3' of the anticodon (position 37) is denoted tRNA(m¹G37)methyltransferase or TrmD⁺. The various mutant forms of it are denoted TrmD and the allele number of the mutation (e.g., TrmD3). The various mutated tRNAs are denoted by their allele designation in front of tRNA (e.g., *sufA6* tRNA is the tRNA^{Prog}_{CG} derivative that has an extra G next to and 3' of the m¹G37.

Bacteria and growth conditions

The bacterial strains used were all derivatives of *S. typhimurium* LT2 (Table 4). Cells were grown in either MOPS minimal medium supplemented with 0.4% glucose (Neidhardt et al., 1974) or Rich-MOPS medium (Neidhardt et al., 1977) when defined media were used. As the complex medium (NAA), Difco nutrient broth (0.8%; Difco Laboratories, Detroit, Michigan), supplemented with 0.5% NaCl, adenine, tryptophan, tyrosine, phenylalanine, and the three aromatic vitamins p-hydroxybenzoate, 2,3-dihydroxybenzoate, and p-aminobenzoate, was used. All supplements were provided at concentrations recommended by Davis et al. (1980).

Genetic procedures

The *E. coli* plasmids used in this work were transferred by transformation first into the *Salmonella* strain GT907, which contains the *galE503*, *hsdL66*, and *hsdA29* mutations. The *galE503* mutation makes the *S. typhimurium* strain competent for transformation (MacLachlan & Sanderson, 1985), the *hsd*-mutations abolish the restriction of *E. coli* DNA, but the strain has an intact DNA modification system. Plasmids were moved from strain GT907 to various *Salmonella* strains by transduction with phage P22 HT105(*int-201*) (Schmieger, 1972; Davis et al., 1980).

Analysis of m¹G content in bulk tRNAs

Strains were grown in MOPS-Glucose medium at 37 °C from about 5 Klett units (approximately 2×10^7 cells/mL) to 100 Klett units (approximately 4×10^8 cells/mL). tRNA was prepared as described by Buck et al. (1983) and digested with nuclease P1 followed by alkaline phosphatase treatment (Gehrke et al., 1982). The hydrolysates were analyzed by HPLC according to the method of Gehrke & Kuo (1990). To determine the level of m¹G37 in tRNA from cells grown at 42 °C, we pregrew the strains at 30 °C to early log-phase and then diluted the cell suspensions to 8 Klett units in medium prewarmed to 42 °C. Cells were then grown to about 4×10^8 cells (100 Klett units) and tRNA was prepared and analyzed as described above. In such an analysis, no more than 10% of the cells would originate from culture grown at 30 °C. Although the double mutant trmD1, sufA6 does not grow at 42 °C, still there is a tenfold increase in mass before this double mutant stops growing. Moreover, we have also specifically labeled the methylated nucleosides synthesized at 42 °C by supplementing the growth medium with ¹⁴C-methylL-methionine. Transfer RNA was prepared and digested to nucleosides and the distribution of methylated nucleosides was analyzed by HPLC (Gehrke & Kuo, 1990). The radioactivity in the eluate was monitored by a flow scintillation analyzer (Radiomatic FLO-ONE beta; Packard Instrument Co., Meriden, Connecticut).

DNA sequencing with PCR amplified template

Two primers complementary to sequences upstream (-92 to -67) and downstream (+177 to +198) of the E. coli proK gene (structural gene for tRNA^{Pro}_{CGG}; Kuchino et al., 1985) were used to amplify by PCR the Salmonella counterpart. Primer 1: 5'-AGCGGCCTGCTGACTTTCTCGCCGAT-3'; primer 2: 5'-BIOTIN-GCCGTTGCTGGCGCAACGTTC-3'. The biotinylated primer binds to the antisense strand and is therefore complementary to the tRNA. After a standard PCR reaction, the amplified product was incubated at room temperature for 12 h with 1 mg Dynabeads M-280 pre-washed with TE buffer (10 mM Tris-HCI (pH 8.0) containing 1 M NaCI as recommended by the Dynal Company, Norway). The Dynabeads were then washed three times with deionized water and incubated in 20 μ L of 0.15 M sodium hydroxide at room temperature for 1 h to separate the strands. The Dynabeads, now containing the sense strand of the tDNA, were used either as template for DNA sequencing or as probe to isolate tRNA^{Pro}_{CGG}. When *proL* (structural gene for tRNA^{Pro}_{CGG}) was amplified, primer 1 (5'-GGGAATTCTGCTGCTGCAAGTGC-3') and primer 2 (5'-BIOTIN-GGGTCCCCCGTTGCTTTCCCG-3') were used. These two primers were designed according to sequence data obtained by Sroga et al. (1992). The chromosomal fragment carrying the trmD gene was amplified with primers 5'-BIOTIN-GCTCTTGTTCAAGTTGCT-3' and 5'-GGATCCTGGTTTTTAAACCACCG-3' according to the earlier established sequence for trmD of S. typhimurium (Ref. EMBL data, accession number x74933) and the sequence of the $trmD^+$ allele obtained by us was the same as obtained earlier.

Purification of tRNA^{Pro}CGG and tRNA^{Pro}GGG

Cells were pregrown at 37 °C in low phosphate (0.5 mM) MOPS-glucose medium from about 5 Klett units (approximately 2×10^7 cells/mL) for 2–3 generations. At this time, 5 mL of each culture were transferred to a tube containing 0.5 mCi ³²P-orthophosphate (10 mCi/mL, Amersham, England) according to the method described by Yarus et al. (1986). The growth of the control culture in medium containing no radioactive phosphate was monitored and the labeled culture was harvested when the control culture had reached 100 Klett units. Cells were pelleted and resuspended in 1 mL of buffer A (10 mM MgAc2, 50 mM NaAc, and 150 mM NaCl, pH 4.5) and an equal amount of phenol saturated with H₂O was added. The mixture was shaken at room temperature for 20 min. The supernatant containing the total RNA was extracted once more with chloroform to remove the phenol and was then lyophilized. tRNA and rRNA were separated on a 12% native polyacrylamide gel. After a short exposure (a few minutes) to an X-ray film, the tRNA band was cut out. The gel slices were mixed with 150 μ L hybridization buffer (6 × SSC, $2 \times$ Denhart, 50% formamide, and 0.1% SDS) and shaken

overnight at 37 °C to extract the tRNA. Such bulk tRNA preparations were then mixed with Dynabeads containing the respective sense strand of the tDNA and denatured at 95 °C for 5 min. After hybridization at 42 °C overnight, the beads were washed at 42 °C with 2 × SSC, 0.1% SDS for 15 min, 1 × SSC, 0.1% SDS for 30 min, and finally stringently washed with 0.1 × SSC, 0.1% SDS for 15 min. Each hybridized tRNA sample was dissociated from the DNA with 15 μ L 0.15M NaOH at 65 °C for 5 min and purified once more by 12% PAGE. The last step was omitted in the latter part of the study, because we found that only one tRNA species was present in the eluted sample. Moreover, in the later stage of the investigation, the hybridized tRNA was dissociated from the DNA by incubating the sample in 200 μ L of Milli-Q H₂O at 95 °C for 5 min instead of treatment with NaOH.

Measurement of the m^1G content in tRNA^{Pro}_{CGG} and tRNA^{Pro}_{GGG} by two-dimensional thin-layer chromatography

Purified tRNA (10,000–20,000 cpm) was digested to nucleotides with nuclease P1 (Gehrke et al., 1982). The hydrolyzed tRNAs were applied on cellulose-coated plastic thin-layer chromatography plates. The chromatograms were developed in the first dimension using the solvent isobutyric acid–25% NH₃-H₂O (50/1.1/28.9 by volume) and in the second dimension using solvent HCI-isopropanoI-H₂O (15/70/10 by volume; Nishimura, 1979). The radioactivity of each of the nucleotides was measured using a PhosphorImager from Molecular Dynamics (England). The average radioactivity from each mole of nucleotide was calculated as the total amount of the radioactivity from the various spots divided by the number of nucleotides in the tRNA. The molar yield of m¹G was thereafter calculated as radioactivity of the spot correlated to m¹G divided by the average value.

Detection of tRNA^{Pro}_{CGG} and tRNA^{Pro}_{GGG} by Northern blot analysis

Total tRNA was prepared and fractionated at acidic pH in the cold according to Varshney et al. (1991) to preserve the aminoacylated tRNA species. Transfer RNA samples were deacylated by incubation for 20 min at 37 °C in 0.5 M Tris-HCl, pH 9.0. The Northern blot and hybridization experiments were carried out as described (von Pawel-Rammingen et al., 1992). ³²P end-labeled oligonucleotide 5'-CCCCCGACACCCC ATGACGGTGC-3' (complementary to nucleosides 24–46 in tRNA^{Pro}_{GGG}) and 5'-CCCCTTCGTCCCGAACGAAGTGC-3' (complementary to nucleosides 24–46 in tRNA^{Pro}_{CGG}) were used to detect these two tRNA species. The amount of each tRNA species synthesized was expressed as the total cpm of the bound probe per μ g of total tRNA applied on the gel.

Western blot analysis

The level of the TrmD peptide in different mutants was measured by Western blot analysis. The rabbit polyclonal antibody used was raised against highly purified tRNA (m¹G37)methyltransferase from *E. coli* and kindly provided by Dr. Michael Holmes, Richmond, Virginia, USA. Cells were

grown in MOPS-Glucose medium at 37 °C or NAA medium at 42 °C from 5 klett units to 100 klett units. Cells were concentrated 50-fold in buffer A (6 mM K₂PO₄, pH 7.3, 6 mM β -mercaptoethanol, 1 mM EDTA, 10% ethylene glycol) and disrupted by sonication. No significant difference in the level of the TrmD peptide in the various mutants was observed whether or not protease inhibitors (chymostatin, leupeptin, pepstatin A, PMSF, and benzamidin) were included in the sample buffer. Thus, we believe that the level of the various TrmD polypeptides reflects the in vivo level and is not caused by protein degradation during the extraction procedure. Samples containing 20 μ g of total cell protein were separated on 15% SDS PAGE and electrophoretically transferred to a nitrocellulose membrane (Hybond-C, Amersham, England). The streptavidin-HRP labeled secondary antibody specific for rabbit Ig was provided by an ECL[™] kit (Amersham, England).

ACKNOWLEDGMENTS

This work was supported by the Swedish Cancer Society (project 680) and the Swedish Natural Science Research Foundation (BU-2930). We are indebted to Dr. Michael Holmes, who provided purified tRNA(m¹G37) methyltransferase, which was used to raise polyclonal antibodies from rabbits. Gunilla Jäger is acknowledged for the development of the antibodies and testing their specificity. We thank Kerstin Jacobsson for excellent technical assistance in performing HPLC analysis and we are especially grateful to Drs. Diarmaid Hughes, Victoria Shingler, Kerstin Stråby, Mikael Wikström, Anders Byström, Britt Persson and Jian-min Liu for critical reading of the manuscript.

Received May 22, 1998; returned for revision July 7, 1998; revised manuscript received December 4, 1998

REFERENCES

- Björk GR. 1986. Transfer RNA modification in different organisms. *Chem Scr 26B*:91–95.
- Björk GR. 1995. Biosynthesis and function of modified nucleosides in tRNA. In: Söll D, RajBhandary UL, eds. tRNA: Structure, biosynthesis, and function. Washington, DC: ASM Press. pp 165–205.
- Björk GR, Wikström PM, Byström AS. 1989. Prevention of translational frameshifting by the modified nucleoside 1-methylguanosine. *Science 244*:986–989.
- Buck M, Connick M, Ames BN. 1983. Complete analysis of tRNA-modified nucleosides by high-performance liquid chromatography: The 29 modified nucleosides of *Salmonella typhimurium* and *Escherichia coli* tRNA. *Anal Biochem* 129:1–13.
- Cermakian N, Cedergren R. 1998. Modified nucleosides always were: An evolutionary model. In: Grosjean H, Benne R, eds. *Modification and editing of RNA*. Washington, DC: ASM Press. pp 535– 541.
- Curnow AW, Garcia GA. 1995. tRNA-guanine transglycosylase from *Escherichia coli*—minimal tRNA structure and sequence requirements for recognition. *J Biol Chem* 270:17264–17267.
- Davis W, Botstein D, Roth JR. 1980. A manual for genetic engineering: Advanced bacterial genetics. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.
- Droogmans L, Haumont E, de Henau S, Grosjean H. 1986. Enzymatic 2'-O-methylation of the wobble nucleoside of eukaryotic tRNAPhe: Specificity depends on structural elements outside the anticodon loop. *EMBO J 5*:1105–1109.
- Edqvist J, Blomqvist K, Stråby KB. 1994. Structural elements in yeast tRNAs required for homologous modification of guanosine-26 into dimethylguanosine-26 by the yeast Trm1 tRNA-modifying enzyme. *Biochemistry* 33:9546–9551.

- Gehrke CW, Kuo KC. 1990. Ribonucleoside analysis by reversedphase high performance liquid chromatography. In: Gehrke CW, Kuo KCT, eds. *Chromatography and modification of nucleosides. Part A. Analytical methods for major and modified nucleosides.* Amsterdam: Elsevier. pp A3–A71.
- Gehrke CW, Kuo KC, McCune RA, Gerhardt KO, Agris PF. 1982. Quantitative enzymatic hydrolysis of tRNAs: Reversed-phase highperformance liquid chromatography of tRNA nucleosides. J Chromatogr A 230:297–308.
- Grosjean H, Edqvist J, Stråby KB, Giegé R. 1996. Enzymatic formation of modified nucleosides in tRNA: Dependence on tRNA architecture. J Mol Biol 255:67–85.
- Gu XR, Ivanetich KM, Santi DV. 1996. Recognition of the T-arm of tRNA by tRNA (m(5)U54)-methyltransferase is not sequence specific. *Biochemistry* 35:11652–11659.
- Gu XR, Yu M, Ivanetich KM, Santi DV. 1998. Molecular recognition of tRNA by tRNA pseudouridine 55 synthase. *Biochemistry* 37:339–343.
- Hong JS, Ames BN. 1971. Localized mutagenesis of any specific small region of the bacterial chromosome. *Proc Natl Acad Sci* USA 68:3158–3162.
- Ikemura T. 1981. Correlation between the abundance of *Escherichia coli* transfer RNAs and the occurrence of the respective codons in its protein genes. *J Mol Biol 146*:1–21.
- Kuchino Y, Mori F, Nishimura S. 1985. Structure and transcription of the tRNAPro1 gene from *Escherichia coli*. Nucleic Acids Res 13:3213–3220.
- Kuchino Y, Yabusaki Y, Mori F, Nishimura S. 1984. Nucleotide sequences of three proline tRNAs from *Salmonella typhimurium*. *Nucleic Acids Res* 12:1559–1562.
- Leung HCE, Chen YQ, Winkler ME. 1997. Regulation of substrate recognition by the MiaA tRNA prenyltransferase modification enzyme of *Escherichia coli* K-12. *J Biol Chem* 272:13073–13083.
- Li JN, Esberg B, Curran JF, Björk GR. 1997. Three modified nucleosides present in the anticodon stem and loop influence the in vivo aa-tRNA selection in a tRNA-dependent manner. *J Mol Biol* 271:209–221.
- MacLachlan PR, Sanderson KE. 1985. Transformation of Salmonella typhimurium with plasmid DNA: Differences between rough and smooth strains. J Bacteriol 161:442–445.
- Motorin Y, Bec G, Tewari R, Grosjean H. 1997. Transfer RNA recognition by the *Escherichia coli* Delta (2)-isopentenyl-pyrophosphate:tRNA Delta 2-isopentenyl transferase: Dependence on the anticodon arm structure. *RNA* 3:721–733.
- Nakanishi S, Ueda T, Hori H, Yamazaki N, Okada N, Watanabe K. 1994. A UGU sequence in the anticodon loop is a minimum requirement for recognition by *Escherichia coli* tRNA-guanine transglycosylase. *J Biol Chem* 269:32221–32225.
- Neidhardt FC, Bloch PL, Pedersen S, Reeh S. 1977. Chemical measurement of steady-state levels of ten aminoacyl-transfer ribonucleic acid synthetases in *Escherichia coli. J Bacteriol 129*:378–387.

- Neidhardt FC, Bloch PL, Smith DF. 1974. Culture medium for enterobacteria. J Bacteriol 119:736–747.
- Newmark RA, Cantor CR. 1968. Nuclear magnetic resonance study of the interactions of guanosine and cytidine in dimethyl sulfoxide. J Am Chem Soc 90:5010–5017.
- Nishimura S. 1979. Chromatographic mobilities of modified nucleosides. In: Schimmel PR, Söll D, Abelson JN, eds. *Transfer RNA: Structure, properties, and recognition.* Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press. pp 551–552.
- Qian Q, Björk GR. 1997. Structural requirements for the formation of 1-methylguanosine in vivo in tRNA^{pro}_{GGG} of *Salmonella typhimu-rium. J Mol Biol 266*:283–296.
- Qian Q, Li J-N, Zhao H, Hagervall TG, Farabaugh PJ, Björk GR. 1998. A new model for phenotypic suppression of frameshift mutations by mutant tRNAs. *Mol Cell* 1:471–482.
- Redlak M, AndraosSelim C, Giege R, Florentz C, Holmes WM. 1997. Interaction of tRNA with tRNA (guanosine-1)methyltransferase: Binding specificity determinants involve the dinucleotide G(36)pG(37) and tertiary structure. *Biochemistry* 36:8699–8709.
- Riddle DL, Roth JR. 1970. Suppressors of frameshift mutations in *Salmonella typhimurium. J Mol Biol 54*:131–144.
- Riddle DL, Roth JR. 1972. Frameshift suppressors. III. Effects of suppressor mutations on transfer RNA. J Mol Biol 66:495–506.
- Romier C, Reuter K, Suck D, Ficner R. 1996. Crystal structure of tRNA-guanine transglycosylase: RNA modification by base exchange. *EMBO J* 15:2850–2857.
- Schmieger H. 1972. Phage P22-mutants with increased or decreased transduction abilities. Mol Gen Genet 119:75–88.
- Sprinzl M, Horn C, Brown M, Ioudovitch A, Steinberg S. 1998. Compilation of tRNA sequences and sequences of tRNA genes. *Nucleic Acids Res* 26:148–153.
- Sroga GE, Nemoto F, Kuchino Y, Björk GR. 1992. Insertion (*sufB*) in the anticodon loop or base substitution (*sufC*) in the anticodon stem of tRNA^{Prol} from *Salmonella typhimurium* induces suppression of frameshift mutations. *Nucleic Acids Res* 20:3463– 3469.
- Svensson I, Boman HG, Eriksson KG, Kjellin K. 1963. Studies on microbial RNA. I. Transfer of methyl groups from methionine to soluble RNA from *Escherichia coli*. J Mol Biol 7:254–271.
- Varshney U, Lee CP, RajBhandary UL. 1991. Direct analysis of aminoacylation levels of tRNAs in vivo. Application to studying recognition of *Escherichia coli* initiator tRNA mutants by glutaminyl-tRNA synthetase. *J Biol Chem 266*:24712–24718.
- von Pawel-Rammingen U, Åström S, Byström AS. 1992. Mutational analysis of conserved positions potentially important for initiator tRNA function in Saccharomyces cerevisiae. *Mol Cell Biol 12*: 1432–1442.
- Yarus M, Cline S, Raftery L, Wier P, Bradley D. 1986. The translational efficiency of tRNA is a property of the anticodon arm. *J Biol Chem 261*:10496–10505.



Structural alterations of the tRNA(m1G37)methyltransferase from Salmonella typhimurium affect tRNA substrate specificity.

J N Li and G R Björk

RNA 1999 5: 395-408

License

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here.